Sensationalist news sources have been quick to amplify fears regarding a potential stock market crash, yet credible market experts are anticipating a more measured, if not mundane, outcome.
Prominent voices in the industry present a range of predictions. Morgan Stanley has stated that it sees “continued equity gains in 2026,” albeit with modest growth, as much good news is already reflected in current prices. Fidelity echoes this sentiment, suggesting that 2026 could be another positive year for the market but not without risks that should not be ignored.
Oppenheimer is predicting a bullish scene, highlighting a “broadening of the powerful rally” that commenced in 2022, fuelled by resilient earnings and easing inflation. Goldman Sachs’ strategy team estimates recession odds at 25%, forecasting continued economic expansion and projecting a base-case stock market return of 7% alongside 10% earnings growth in 2026. Bloomberg’s survey further supports this outlook, estimating a base case of approximately 2.1% real GDP growth in the U.S. and a favorable environment for risk assets.
Conversely, there are analysts who adopt a more pessimistic stance. Veteran Wall Street analyst Marc Chaikin warns of a “65% chance of a bear market in 2026,” with anticipated average losses around 20%. He positions himself as a contrarian, claiming a downturn not anticipated by most of his peers. Similarly, David Rosenberg observes that major surveys reveal “not a single economist” predicting a recession in 2026, viewing this as a potential red flag.
In light of these contrasting views, a prudent approach is essential for investors. While fears of a crash might be inflated, a number of genuine risks remain. Schwab has succinctly identified four primary concerns: the potential for an AI bubble, persistent inflation, credit market stresses, and political gridlock in Washington. Although these issues are primarily U.S.-focused, their effects could reach markets in the UK and beyond.
Investors have two main strategies available: they could liquidate their positions to wait for more favorable conditions, but this carries the risk of re-entering the market at higher prices if conditions improve unexpectedly. Alternatively, a more sensible approach during uncertain times would be to allocate portfolios towards recession-resistant stocks, such as those in the healthcare, utilities, or consumer staples sectors. These industries are known for maintaining steady demand even in economic downturns. This dual strategy allows for mild growth in stable conditions and minimal losses in the event of a downturn.
One stock gaining attention as a safe investment for 2026 is pharmaceutical giant GSK (LSE: GSK), as highlighted by analysts from AJ Bell. GSK offers a 3.5% yield supported by a robust dividend policy, a clear growth strategy, and a history of resilience. In its recent Q3 results, two of its key divisions recorded growth rates of 15% to 16%, while its vaccines division generated £2.7 billion in sales. Significantly, GSK maintains a diversified pipeline of new drugs, many nearing completion in late-stage clinical trials. This aspect is crucial for mitigating risks associated with patent expirations, which often lead to substantial revenue declines as generics enter the fray.
If successful, GSK’s new drug pipeline could provide sufficient cash flow to offset losses from expiring patents. While no investment is without risks, historical data suggests positive outcomes, with GSK achieving total returns of around 63% over the past five years.
